Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Living With Multiple Myeloma: Nurses as the Lifeline

October 7th 2011

In 2001, Doug Rickert, a 46-year-old industrial management consultant and married father of 3, heard the life-altering words, "softball-sized tumor pressing against your spinal canal."

Pharmaceutical Company Profile: Celgene Corporation

September 30th 2011

Through the success of Revlimid and other drugs, Celgene has become a respected and powerful player in the biopharmaceutical industry in recent years.

Brentuximab Vedotin Proves Effective Against Lymphomas

September 27th 2011

Brentuximab vedotin showed very positive results in lymphoma patients in several early trials, prompting the FDA's Oncologic Drugs Advisory Committee to unanimously recommend accelerated approval for the drug.

Back on the Horse: Ron Rogers

August 24th 2011

You'd never know that Rogers has had multiple myeloma for almost 11 years -- and that's just the way he likes it.

ASCO Highlights: Trials in Progress

August 23rd 2011

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Updates on Multiple Myeloma Diagnosis and Treatment Strategies

August 23rd 2011

Progress in our understanding of multiple myeloma pathogenesis has led to the identification of new therapeutic targets.

FDA Approves Brentuximab Vedotin for 2 Types of Lymphoma

August 19th 2011

The FDA announced that brentuximab vedotin has been approved for the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Evolving Strategies Using Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Non-Hodgkin Lymphoma

August 17th 2011

Diffuse large B-cell non-Hodgkin lymphoma is typically a chemotherapy-sensitive malignancy, justifying dose-intense therapy with hematopoietic stem cell transplantation for patients unlikely to achieve cure with standard-dose regimens.

Investigational Agent Provides Hope for Patients With Myelofibrosis

August 15th 2011

Treating myelofibrosis with the investigational JAK inhibitor ruxolitinib holds promise.

Accelerating Changes in Oncology

August 12th 2011

A look at dramatic changes in the landscape of multiple myeloma that have occurred over the past decade and new developments in the context of stem cell transplantation in non-Hodgkin lymphoma.

JAK-STAT Signaling Has Many Faces: Inhibitors Offer Hope in Rare Blood Cancers

July 27th 2011

Intense research has resulted in JAK-STAT becoming one of the best-understood signal transduction cascades.

3 Questions for Srdan Verstovsek, MD, PhD

July 26th 2011

Srdan Verstovsek, MD, PhD, is a medical oncologist and associate professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston.

Novel Therapies Usher in New Era

July 26th 2011

Every decade during the past 50 years, treatment for multiple myeloma has taken a leap forward.

Ruxolitinib Results Promising in 2 Myelofibrosis Studies

July 25th 2011

Ruxolitinib, an investigational JAK inhibitor, demonstrated significant benefits for patients with myelofibrosis.

Reynaldo Garcia on CML BCR-ABL Testing

July 25th 2011

Reynaldo Garcia From Lineberger Comprehensive Cancer Center on CML BCR-ABL Testing Recommendation

FDA Panel Unanimously Supports New Lymphoma Treatment

July 15th 2011

ODAC unanimously recommended accelerated approval for brentuximab vedotin (Adcetris) in 2 types of lymphoma.

Life Persists: One Fellow Finds Hope Amid Cancer's Destruction

July 13th 2011

It was midnight and I had just been jarred out of a sound sleep by the startlingly repetitive beeping of my pager.

Using Extracorporeal Photopheresis in the Treatment of Graft-Versus-Host Disease

June 30th 2011

Extracorporeal photopheresis takes approximately 3 to 4 hours to complete and involves leukapheresis, separation of the buffy coat, photoactivation, and finally reinfusion.

Dr. Smith Discusses Lymphoma in the Elderly

June 24th 2011

Dr. Sonali Smith director Lymphoma Program at the University of Chicago Medical Center Discusses Lymphoma in the Elderly

OncLive June 2011 FDA Digest

June 23rd 2011

FDA digest from June discussing warning labels, pancreatic treatment choices, and the quest for a lymphoma drug.